Health Trials

Clinical trials

5

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

VBC117First-in-Human Trial of VBC117 in Participants With Advanced Malignant Solid Tumors

Detailed Description: This is a multicenter, open-label, multiple-dose, first in human(FIH) Phase 1/2a trial. The Phase 1 portion uses the Bayesian optimal interval (BOIN) design to escalate doses and determine the maximum tolerated dose(MTD) and/or recommended phase 2 dose(RP2D) with potential backfill cohorts. The Phase 2a portion consists of dose optimization followed by cohort expansion to confirm safety and tolerability and further evaluate the efficacy of the selected RP2D in selected solid tumor malignancies treated with VBC117.

Participants needed: 260
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: VelaVigo Bio IncUpdated: Aug 19, 2026Locations: 12
Eligibility criteria

The participant or the participant's legally acceptable representative is willin... [+7]

Any unresolved toxicity of Grade ≥2 from previous anti-cancer treatment. [+4]

Read more
Status: Recruiting

First-in-Human Trial of VBC101 in Participants With Advanced Solid Tumor Malignancies

This is a multicenter, open-label, multiple-dose, FIH Phase 1/2a trial. The Phase 1 portion adopts an accelerated titration for the first dose level, followed by BOIN design to identify the MTD and/or RP2D with potential backfill cohorts. The Phase 2a portion consists of dose optimization followed by cohort expansion to confirm safety and tolerability and to further evaluate the efficacy of the selected RP2D in selected solid tumor malignancies for VBC101.

Participants needed: 310
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: VelaVigo Bio IncUpdated: Jul 23, 2026Locations: 5
Eligibility criteria

1. The participant or the participant's legally acceptable representative is wil... [+9]

2. Known or suspected brain metastases, or spinal cord compression, unless the c... [+3]

Read more
Status: Not yet recruiting

First-in-Human Trial of VBC106 in Participants With Advanced Solid Tumors

This is a multicenter, open-label, multiple-dose, FIH Phase 1/2a trial. The Phase 1 portion adopts BOIN design to identify the MTD and/or RP2D with potential backfill cohorts. The Phase 2a portion consists of dose optimization followed by cohort expansion to confirm safety and tolerability and to further evaluate the efficacy of the selected RP2D in selected solid tumor malignancies for VBC106.

Participants needed: 260
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: VelaVigo Bio IncUpdated: Jul 9, 2026Locations: 4
Eligibility criteria

1. The participant or the participant's legally acceptable representative is wil... [+8]

Any unresolved toxicity of Grade ≥2 from previous anti-cancer treatment. [+5]

Read more
Status: Not yet recruiting

First-in-Human Trial of VBC108 in Participants With Advanced Malignant Solid Tumors

This is a multicenter, open-label, multiple-dose, FIH Phase 1/2a trial. The Phase 1 portion uses Bayesian optimal interval (BOIN) design to escalate and determine the MTD and/or RP2D with potential backfill cohorts. The Phase 2a portion consists of dose optimization followed by cohort expansion to confirm safety and tolerability and to further evaluate the efficacy of the selected RP2D in selected solid tumor malignancies for VBC108.

Participants needed: 230
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: VelaVigo Bio IncUpdated: Jul 13, 2026Locations: 12
Eligibility criteria

The participant or the participant's legally acceptable representative is willin... [+8]

Any unresolved toxicity of Grade ≥2 from previous anti-cancer treatment. [+4]

Read more
Status: Recruiting

Clinical Trial of VBC103 in Patients With Advanced Malignant Solid Tumors

This study is a multicenter, open-label, multi-dose, first-in-human (FIH) Phase I/IIa study to determine the safety and tolerability of VBC103, as well as the maximum tolerated dose (MTD) and/or recommended Phase II dose (RP2D), PK and further evaluate its efficacy.

Participants needed: 255
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: VelaVigo Bio IncUpdated: Apr 22, 2026Locations: 1
Eligibility criteria

1.The subject or their legal representative is willing and able to sign a writte... [+7]

1.Any unresolved ≥Grade 2 toxicity from prior anticancer therapy. [+3]

Read more